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It is not well established whether the incident outcomes of the 
clinical high-risk (CHR) syndrome for psychosis are diag-
nostically specific for psychosis or whether CHR patients 
also are at elevated risk for a variety of nonpsychotic disor-
ders. We collected 2 samples (NAPLS-1, PREDICT) that 
contained CHR patients and a control group who responded 
to CHR recruitment efforts but did not meet CHR crite-
ria on interview (help-seeking comparison patients [HSC]). 
Incident diagnostic outcomes were defined as the occurrence 
of a SIPS-defined psychosis or a structured interview diag-
nosis from 1 of 3 nonpsychotic Diagnostic and Statistical 
Manual of Mental Disorders, Fourth Edition (DSM-IV) 
groups (anxiety, bipolar, or nonbipolar mood disorder), when 
no diagnosis in that group was present at baseline. Logistic 
regression revealed that the CHR vs HSC effect did not 
vary significantly across study for any emergent diagnostic 
outcome; data from the 2 studies were therefore combined. 
CHR (n = 271) vs HSC (n = 171) emergent outcomes were: 
psychosis 19.6% vs 1.8%, bipolar disorders 1.1% vs 1.2%, 
nonbipolar mood disorders 4.4% vs 5.3%, and anxiety dis-
orders 5.2% vs 5.3%. The main effect of CHR vs HSC was 
statistically significant (OR = 13.8, 95% CI 4.2–45.0, df = 
1, P < .001) for emergent psychosis but not for any emergent 
nonpsychotic disorder. Sensitivity analyses confirmed these 
findings. Within the CHR group emergent psychosis was 
significantly more likely than each nonpsychotic DSM-IV 
emergent disorder, and within the HSC group emergent 
psychosis was significantly less likely than most emergent 
nonpsychotic disorders. The CHR syndrome is specific as a 
marker for research on predictors and mechanisms of devel-
oping psychosis.
Key words: validity/bipolar disorder/nonbipolar mood 
disorder/anxiety disorder
Introduction
For the past 30  years efforts have been made to iden-
tify signs of psychosis as early as possible,1–6 with the 
ideal goal of identifying individuals at risk for psychosis 
before symptoms fully manifest. The hope is that early 
identification may lead to faster clinical engagement 
that delays or prevents transition to full-blown cases of 
this possibly devastating disease. There is evidence that 
early intervention in patients with established psychosis 
leads to improved outcomes,7–9 and preliminary evidence 
that intervening before the onset of frank psychosis may 
reduce subsequent disease burden.10–12
Centers specializing in early psychosis detection typ-
ically use structured diagnostic instruments such as 
the SIPS13 or Comprehensive Assessment of  At-Risk 
Mental States.14 These instruments are administered 
by specially trained personnel and examine symptom 
severity in multiple domains of  psychotic behavior 
and general mental health functioning in order to clas-
sify those likely to be at clinical high risk (CHR) for 
eventual conversion to psychosis. Use of  the SIPS car-
ried a low rate of  endorsement for the most common 
CHR syndrome in an epidemiologic sample,15 and use 
of  these instruments carries a positive predictive value 
of  32% for conversion to psychosis at 3 years in clini-
cal samples of  help-seeking CHR subjects assessed by 
high-risk services.16
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While structured rating instruments provide a useful 
risk assessment for conversion to psychosis, there has 
been concern about whether clinical outcomes in CHR 
patients are specific to psychosis, or whether patients so 
identified are generally at increased risk for many psychi-
atric disorders.17–19 This concern arises in part because 
most CHR subjects do not go on to develop full psycho-
sis,16 and in part because two-thirds or more of CHR 
subjects have other comorbid Axis I diagnoses at ascer-
tainment,20–25 primarily affective and anxiety disorders, 
that contribute to the functional deficits21 and psycho-
pathologic symptoms21 seen in CHR samples.
Whether CHR points specifically to risk for future psy-
chosis vs to nonspecific deterioration in mental health 
has clear research and policy implications. If  the CHR 
designation offers no specific prognosis with regard to 
psychosis, then making a CHR assessment may be of lit-
tle additional help beyond general mental health screen-
ing, because it would not differentiate a need for specialty 
treatment programs aimed at psychosis. Moreover, 
research studies of CHR would not be investigating risk 
factors or biomarkers that are specific for psychosis but 
rather general risk factors for a mixture of mental disor-
ders. In fact, a recent study found that affective/anxiety 
comorbidity in CHR patients was associated with lower 
gray matter volumes in anterior cingulate than in CHR 
patients without comorbidity.26
Understanding whether a CHR designation specifically 
delineates risk for developing psychosis necessarily relies 
on comparing incident rates of psychosis vs incident rates 
of other classes of psychiatric disorders. Unfortunately, 
however, while baseline comorbidity of psychiatric dis-
orders in CHR patients is already well described, only 
1 study has examined incident nonpsychotic diagnostic 
outcomes in CHR patients,27 and we are aware of none 
that have directly compared such outcomes in CHR with 
those from psychiatric patients who did not meet CHR 
criteria. We therefore conducted the present analyses 
using data from 2 large naturalistic samples.
Method
We report data from 2 cohorts of CHR syndrome patients 
that each also included a comparison group of patients 
who did not meet criteria for CHR syndrome or psycho-
sis. The comparison patients are termed “help-seeking 
comparison subjects” (HSCs). Both CHR and HSC 
patients responded to CHR recruitment efforts, passed 
a phone screen designed to eliminate those who had no 
target symptoms or were obviously psychotic, and were 
invited to and underwent SIPS evaluation. CHR patients 
met SIPS criteria at evaluation, and HSC patients did 
not. These patient groups have been shown to differ on 
rate of conversion to psychosis, positive and negative 
symptoms, current functioning, mood disorder comor-
bidity, and family history.25 A recent meta-analysis of 11 
studies confirms the higher risk of psychosis in the CHR 
patients vis-a-vis HSC, with an OR estimate of 20.2.28
The present 2 cohorts were the first sample of the North 
American Prodromal Longitudinal Study (NAPLS-1) 
and the PREDICT study. Our newer NAPLS-2 sample29 
did not follow HSCs or collect detailed baseline data on 
them. Methods for NAPLS-130 and PREDICT31 have 
been reported previously.
Subjects
NAPLS-1 merged data collected at 8 sites on 303 CHR 
syndrome and 135 HSC patients enrolled between early 
1998 and early 2005 and for whom data were available 
for at least 1 follow-up timepoint (supplementary fig-
ure 1).25 The dataset includes interim data from the first 
44 CHR and 24 HSC qualifying patients enrolled in the 
PREDICT study. For the present analyses these subjects 
are included in the PREDICT sample rather than in the 
NAPLS-1 sample, because when the NAPLS-1 dataset 
was closed, PREDICT follow-up was still ongoing. Of 
the remaining 259 CHR and 111 HSC NAPLS-1 patients, 
160 (62%) and 100 (90%), respectively, underwent struc-
tured diagnostic interviews for Diagnostic and Statistical 
Manual of Mental Disorders, Fourth Edition (DSM-IV) 
Axis I  diagnoses at baseline and also at 1 or more fol-
low-up evaluations. Among the HSC patients, 69 (69.0%) 
had no positive symptoms in the SIPS CHR severity 
range at baseline, and 31 (31.0%) had symptoms that met 
severity criteria but not worsening or frequency criteria.
PREDICT was conducted at 3 of the NAPLS-1 sites 
(University of North Carolina, University of Toronto, 
and Yale University), and enrolled 151 CHR syndrome 
and 86 HSC patients between late 2003 and early 2008 
who contributed follow-up data (supplementary fig-
ure 1). Of these, 111 CHR (74%) and 71 HSC (83%) also 
underwent structured diagnostic interviews for DSM-IV 
Axis I diagnoses at baseline and at 1 or more follow-up 
evaluations. Among the HSC patients, 34 (47.9%) had no 
positive symptoms in the CHR severity range at baseline, 
and 37 (52.1%) had symptoms that met severity criteria 
but not worsening or frequency criteria.
Data on the recruitment sources in these 2 studies 
were not collected systematically, but recruitment meth-
ods were broadly similar to those reported in the later 
NAPLS-2 sample, where approximately 15% of both 
CHRs and HSCs were referred by the school/commun-
ity sector, roughly 40% of CHRs and 35% of HSCs were 
referred by the health/mental health sector, and about 
45% of CHRs and 50% of HSCs were referred by self, 
family/friends, or other.29 Inclusion and exclusion criteria 
were also similar in the 2 studies. One exception is that 
CHR and HSC patients in PREDICT could not enroll 
if  they had received antipsychotic medication in the past 





Each site in both studies utilized the Structured Interview 
for Psychosis-risk Syndromes (SIPS) to determine 
whether psychosis and CHR syndrome criteria were 
met.13 Reliability of the SIPS has been reported previ-
ously32–35 and was established in these studies for all sites.30 
Structured assessment of DSM-IV Axis-I diagnoses in 
NAPLS-1 varied somewhat within and across sites,25 with 
most subjects receiving versions of the Structured Clinical 
Interview for DSM-IV (SCID)36 or the Schedule for 
Affective Disorder and Schizophrenia for School-Aged 
Children (K-SADS).37 The Comprehensive Assessment 
of Symptoms and History38 was used for some sub-
jects. PREDICT employed the SCID-NP39 for subjects 
16 and older and the K-SADS37 for those 15 and under. 
Follow-up assessments were available at 6-month inter-
vals in both studies, out to 30 months in NAPLS-1 and to 
48 months in PREDICT. Only follow-up timepoints with 
DSM-IV diagnostic interviews were permitted to contrib-
ute to data analysis.
Depressive and anxiety comorbidities are the most 
common in CHR patients,21 and we felt it important to 
distinguish between bipolar and nonbipolar disorders. 
Accordingly, for both studies nonpsychotic DSM-IV Axis-I 
diagnoses were classified into 3 groups: bipolar disorders 
(DSM-IV nonpsychotic bipolar I disorder, bipolar disor-
der NOS, bipolar II disorder, and cyclothymic disorder), 
nonbipolar mood disorders (DSM-IV nonpsychotic major 
depressive disorder, dysthymic disorder, depressive disorder 
not otherwise specified [NOS], and mood disorder NOS), 
and anxiety disorders (panic disorder with or without ago-
raphobia, generalized anxiety disorder, agoraphobia with-
out panic disorder, social phobia, specific phobia, obsessive 
compulsive disorder, post-traumatic stress disorder, separa-
tion anxiety disorder, and anxiety disorder NOS).
Emergence of psychosis, or “incident psychosis,” 
was defined by SIPS criteria as previously described.25 
Emergent nonpsychotic disorders was defined among 
subjects who did not convert to psychosis as the emer-
gence at any time during follow-up of a DSM-IV diag-
nosis from 1 of the 3 nonpsychotic groups, when no 
diagnosis in that DSM-IV group was present at baseline.
Data on psychotropic medication use at baseline were 
collected in both studies and were reported previously for 
NAPLS-1.40–42 Duration of CHR syndrome data was col-
lected from fields in the SIPS. When more than 1 CHR 
syndrome was present, the longer duration was used. 
Current functioning at baseline was assessed in both 
studies with the Global Assessment of Functioning43 
included in the SIPS.
Statistical Methods
Analyses were conducted using SPSS version 19. P values 
< .05 were considered statistically significant. Baseline 
characteristics were compared using Student’s t tests and 
χ2. In 1 case, 2 incident nonpsychotic disorders emerged 
at the same timepoint (nonbipolar mood disorder and 
anxiety disorder in a PREDICT CHR subject). In order 
to permit initial omnibus multinomial regression and 
2 × 5 χ2 analyses of incident outcome, the nonbipolar 
mood disorder was treated as trumping the anxiety dis-
order. In the remaining analyses this “trumping” rule was 
not applied. The multinomial regression incorporated 
terms for baseline diagnosis (CHR vs HSC) and study 
(NAPLS-1 vs PREDICT).
Logistic regression was used to compare disorder-
specific incident outcome rates, incorporating the same 
terms as for the multinomial regression, with post hoc 2 
× 2 χ2 analyses. Product terms were added to the logis-
tic models to test interaction effects between study and 
baseline CHR vs HSC diagnosis; when models either 
would not converge or did not reach a level of statisti-
cal significance, interaction terms were omitted. When 
baseline characteristics differed significantly across CHR 
and HSC groups in either study, effects of inclusion of 
terms for these characteristics were evaluated in models 
showing significant independent CHR vs HSC effects. 
Effects of baseline characteristics were examined simi-
larly in models showing significant effects of study. The 
primary analyses expressed rates of incident disorder as 
number of emergent cases divided by number of all cases. 
Because rates of baseline disorders varied across CHR 
vs HSC (table  1), sensitivity analyses were conducted 
excluding patients with baseline disorder and expressing 
rates of incident disorder as number of emergent cases 
divided by number of cases not excluded.
Because rates of baseline disorder varied across diag-
nosis, within group comparisons of emergent disorder 
across diagnostic outcome were restricted to pairwise 
analyses vs emergent psychosis and to analyses excluding 
baseline cases of comparator disorder. These compari-
sons employed Cochran’s Q.
Results
Baseline Characteristics
Table  1 compares CHR and HSC samples on base-
line characteristics. CHR patients had higher Scale of 
Psychosis-risk Symptoms (SOPS) total, positive, and 
general symptom scores and higher use rates of any 
psychotropic than HSC in both studies. In NAPLS-1, 
CHR patients were also older and had lower function-
ing scores and higher SOPS negative and disorganization 
scores, higher rates of antipsychotic and antidepressant 
use, and higher rates of any mood/anxiety disorder and 
nonbipolar mood disorder comorbidity than HSC. CHR 
samples differed across study at baseline on age (1.5 years 
younger in NAPLS-1), functioning (lower in NAPLS-1), 
SOPS scores (total, negative, and disorganized all higher 
in NAPLS-1), and antipsychotic and mood stabilizer use 
(both higher in NAPLS-1). CHR syndrome duration 
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was not recorded systematically in NAPLS-1 but when 
recorded was nearly 3 times as long as in PREDICT. HSC 
samples differed at baseline on age (lower in NAPLS-1, 
table 1), SOPS positive symptoms (higher in PREDICT), 
and stimulant use (higher in NAPLS-1).
Incident Diagnoses
The multinomial regression for emergent disorder pro-
duced a highly significant model (χ2 = 67.4, df = 8, P < 
.001), with highly significant main effects of baseline CHR 
vs HSC diagnosis (χ2= 38.1, df = 4, P < .001). Multinomial 
models including baseline CHR vs HSC diagnosis × study 
product terms or restricted to either study would not con-
verge due to zero cells. Main effects of study (NAPLS-1 
vs PREDICT) were also highly significant (χ2= 29.3, df = 
4, P < .001). Follow-up logistic models containing prod-
uct terms testing interactions between CHR vs HSC and 
study would either also not converge (anxiety and bipolar) 
or did not reach a level of statistical significance (nonbi-
polar mood disorder); thus further analyses focused on 
the merged samples (supplementary figure 1).
Logistic regression revealed that the significant effect 
of CHR vs HSC diagnosis on emergent disorder was 
accounted for by effects on emergent psychosis (19.6% 
vs 1.8%, P < .001, figure 1 and supplementary table 1). 
No significant effects of CHR vs HSC diagnosis were 
observed for other emergent disorders (figure 1, supple-
mentary table 2). Logistic regression further revealed that 
CHR vs HSC rates for any emergent nonpsychotic disor-
der (ie, any of bipolar, nonbipolar mood, or anxiety) also 
did not significantly differ, in the merged (supplementary 
table 2) or NAPLS-1 (OR = 1.07, 95% CI 0.41 to 2.85) 
or PREDICT (OR = 0.75, 95% CI 0.34 to 1.68) samples. 
Significant main effects of study were seen for emergent 
psychosis (NAPLS-1 higher) and for emergent anxiety 
disorders (PREDICT higher.
Sensitivity analyses showed that the CHR vs HSC dif-
ference for incident psychosis continued to hold whether 
analyses included or excluded subjects with each or 
any baseline disorder from the model (all p’s ≤ 0.001, 
Table  S1). Similarly, the lack of CHR vs HSC differ-
ences for incident nonpsychotic disorders also continued 
to hold whether models included subjects with baseline 
Table 1. Baseline Characteristics of NAPLS-1 and PREDICT Samples
NAPLS-1 PREDICT
Measure CHR (n = 160)a HSC (n = 100)b CHR (n = 111)c HSC (n = 71)d
Age 18.1 ± 4.4g,j 15.7 ± 2.9i,j 19.6 ± 4.7g 19.3 ± 4.2j
No. male 92 (57.5%) 64 (64.0%) 60 (54.1%) 37 (52.1%)
No. Caucasian 123 (76.9%) 68 (68.0%) 82 (73.9%) 53 (74.6%)
Parental education 5.58 ± 1.69 5.89 ± 1.95 6.00 ± 2.48 5.56 ± 2.37
Global functioning 48.7 ± 11.6i,j 54.9 ± 11.9i 54.9 ± 12.5j 56.2 ± 11.8
CHR duration, dayse 722 ± 1056i NA 261 ± 298i NA
SOPS total 36.6 ± 14.0i,j 22.5 ± 12.5i 30.2 ± 11.3h,j 25.2 ± 13.4h
SOPS positive 11.2 ± 4.2i 4.0 ± 3.4i,k 10.9 ± 3.1j 6.9 ± 4.3j,k
SOPS negative 11.6 ± 6.7f,i 9.9 ± 6.5f 8.4 ± 5.7i 8.7 ± 6.0
SOPS disorganized 6.3 ± 3.7i,j 3.4 ± 3.1h 4.0 ± 2.6j 3.9 ± 3.0
SOPS general 7.9 ± 4.3i 5.4 ± 4.3i 7.0 ± 4.0f 5.7 ± 4.2f
Any mood/anx disorder 122 (76.3%)i 52 (52.0%)i 77 (69.4%) 43 (60.6%)
DSM-IV bipolar 4 (2.5%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
DSM-IV nonbipolar mood 92 (57.5%)i 37 (37.0%)i 54 (48.6%) 27 (38.0%)
DSM-IV anxiety 69 (43.1%) 33 (33.0%) 50 (45.0%) 23 (32.4%)
Any psychotropic 77 (50.0%)g 32 (32.0%)g 48 (43.2%)f 20 (28.2%)f
Antipsychotic 33 (21.4%)g,i 8 (8.0%)g,f 1 (0.9%)i 0 (0.0%)f
Antidepressant 55 (35.7%)f 23 (23.0%)f 39 (35.1%) 17 (23.9%)
Mood stabilizer 9 (5.8%)f 1 (1.0%) 1 (0.9%)f 0 (0.0%)
Stimulant 8 (5.2%) 10 (10.0%)f 5 (4.5%) 1 (1.4%)f
Benzodiazepine 9 (5.8%) 2 (2.0%) 10 (9.0%) 4 (5.6%)
Notes: CHR, clinical high risk; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition; SOPS, Scale of 
Psychosis-risk Symptoms; NA, not applicable.
avaried from 137–160 across measure other than CHR duration.
bvaried from 78–100 across measure.
cn = 111 except for CHR duration.
dvaried from 70–71 across measure.
en = 55 for NAPLS-1 and 105 for PREDICT.
fgroups with these letters differ P < .05.
g/hgroups with these letters differ P < .01.
i/j/kgroups with these letters differ P < .001.
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disorder (as noncases of emergent disorder) or excluded 
them (all p’s ≥ 0.390, Table S2).
Two-by-five and pairwise χ2 analyses (table 2) revealed 
similar findings as the multinomial and logistic regression 
models. CHR and HSC groups significantly differed only 
on incident psychosis, and this difference was significant 
in each study.
Within group comparisons of incident disorder in the 
merged CHR sample showed that emergent psychosis was 
significantly more likely than emergent nonpsychotic dis-
order for each of the 3 individual nonpsychotic classes 
(table  3). Incident psychosis was not significantly more 
likely, however, than any incident nonpsychotic disorder. 
In the NAPLS-1 sample alone, findings were similar or 
stronger than in the merged samples, and incident psycho-
sis did occur significantly more frequently than any inci-
dent nonpsychotic disorder (supplementary table  3). In 
the PREDICT sample alone, however, emergent psychosis 
was significantly more likely than emergent nonpsychotic 
disorder only for bipolar disorder (supplementary table 3).
Within group comparisons of emergent disorder in the 
merged HSC sample showed that emergent psychosis was 
significantly less likely than emergent nonbipolar mood 
disorder, anxiety disorder, or any nonpsychotic disorder 
(table 3). In the NAPLS-1 sample alone, findings were simi-
lar to those in the merged samples, except that there were no 
cases of incident anxiety disorder (supplementary table 4). 
In the PREDICT sample alone, emergent psychosis was 
significantly less likely than emergent anxiety disorder and 
any nonpsychotic disorder (supplementary table 4).
Potential Confounders
Entry of terms for global functioning, SOPS total, pos-
itive, negative, or disorganized symptoms, nonbipolar 
Fig. 1. Incident diagnostic outcomes in combined NAPLS-1 
and PREDICT studies. CHR, clinical high risk (n = 271). 
HSC, help-seeking comparison patients (n = 171). Models also 
contain a term for study. Non-BP: nonbipolar. One subject with 
simultaneous emergent anxiety and nonbipolar mood disorders 
appears in both groups (see text). *CHR vs HSC comparison 
OR = 13.8, 95% CI 4.2–45.0, df = 1, P < .001, no asterisk - n.s., 
(supplementary table 1).
Table 2. Emergent Diagnostic Outcomes by Baseline CHR Diagnosis in Each Study
Study Subjects (n)
Emergent Diagnostic Outcomes (%)
Bipolar Disorder Nonbipolar Mood Anxiety Disorder Psychosis
NAPLS-1 CHR (160) 3 (1.9%)a 7 (4.4%)b 2 (1.3%)c 39 (24.3%)d
HSC (100) 1 (1.0%)e 6 (6.0%)f 0 (0%)g 1 (1.0%)h
PREDICT CHR (111) 0 (0%)i 5 (4.5%)j 12 (10.8%)k 14 (12.6%)l
HSC (71) 1 (1.4%)m 3 (4.2%)n 9 (12.7%)o 2 (2.8%)p
Notes: HSC, help-seeking comparison subject patients; Bipolar Disorder: nonpsychotic, bipolar mood disorder; Nonbipolar Mood: 
nonpsychotic, nonbipolar mood disorder. The 1 subject with simultaneous emergent anxiety and nonbipolar mood disorders appears in 
both columns (see text).
Between-baseline CHR diagnosis comparisons (P < .05 underlined).
2 × 5 analysis of incident disorder— CHR vs HSC overall: χ2 = 30.3 df = 4 P ≤ .001; CHR vs HSC in NAPLS-1: χ2 = 28.3 df = 4 P < 
.001; CHR vs HSC in PREDICT: χ2 = 6.7 df = 4 P = .153.
Pairwise analyses of individual incident disorders— CHR vs HSC in NAPLS-1: a vs e χ2 = 0.3 df = 1 P = .577, b vs f  χ2 = 0.3 df = 1 
P = .559, c vs g χ2 = 1.3 df = 1 P = .262, d vs h χ2 = 25.8 df = 1 P < .001; CHR vs HSC in PREDICT: i vs m χ2 = 1.6 df = 1 P = .210, j vs 
n χ2 = 0.0 df = 1 P = .929, k vs o χ2 = 0.1 df = 1 P = .701, l vs p χ2 = 5.2 df = 1 P = .023.
Pairwise analysis of any incident nonpsychotic disorder— CHR vs HSC overall: 28/271 (10.3%) vs 20/171 (11.7%), χ2 = 0.1 df = 1 
P = .654;  CHR vs HSC in NAPLS-1: 12/160 (8.1%) vs 7/100 (7.0%), χ2 = 0.0 df = 1 P = .880;  CHR vs HSC in PREDICT: 16/111 
(14.4%) vs 13/71 (18.3%), χ2 = 0.5 df = 1 P = .484.
Between-study pairwise comparisons (P < .05 underlined).
2 × 5 analysis of incident disorder— NAPLS-1 vs PREDICT overall: χ2 = 28.6 df = 4 P < .001;  NAPLS-1 vs PREDICT in CHR: 
χ2 = 18.5 df = 4 P < .001;  NAPLS-1 vs PREDICT in HSC: χ2 = 14.6 df = 4 P = .006.
Pairwise analyses of individual incident disorders— NAPLS-1 vs PREDICT in CHR: a vs i χ2 = 2.1 df = 1 P = .147, b vs j χ2 = 0.0 df = 1 
P = .959, c vs k χ2 = 12.2 df = 1 P < .001, d vs l χ2 = 5.7 df = 1 P = .016; NAPLS-1 vs PREDICT in HSC: e vs m χ2 = 0.1 df = 1 P = .807, 
f  vs n χ2 = 0.3 df = 1 P = .609, g vs o χ2 = 13.4 df = 1 P < .001, h vs p χ2 = 0.8 df = 1 P = .373.
Pairwise analysis of any incident nonpsychotic disorder— NAPLS-1 vs PREDICT overall: 19/260 (7.3%) vs 29/182 (15.9%), χ2 = 8.2 df = 
1 P = .004; NAPLS-1 vs PREDICT in CHR: 12/160 (7.5%) vs 16/111 (14.4%), χ2 = 3.4 df = 1 P = .066; NAPLS-1 vs PREDICT in HSC: 
7/100 (7.0%) vs 13/71 (18.3%), χ2 = 5.1 df = 1 P = .023.
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mood disorder, or baseline antipsychotic or antidepressant 
each significantly improved the logistic regression model 
for incident psychosis (supplementary table  5). Most 
reduced the significance of the CHR vs HSC effect, which 
nevertheless remained strong in all cases. Inclusion of 
terms for other variables differing between CHR and HSC 
samples in table 1 did not improve the model. With regard 
to the study effect on emergent psychosis, the NAPLS-1 vs 
PREDICT differences in table 1 each mediated the study 
effect. No baseline differences mediated the study effect on 
emergent anxiety (data available on request).
Discussion
The main finding of the present report is that incident 
diagnostic outcomes of the CHR syndrome were specific 
for psychosis, as compared with a comparison group of 
help-seeking patients who answered CHR recruitment 
efforts but did not meet CHR criteria. Psychosis was the 
only incident disorder that significantly differed between 
CHR and HSC patients in the merged sample or in either 
study; nonpsychotic disorders emerged in CHR patients 
at fairly low rates that were no higher than those in HSC 
patients. We also note, in the merged sample, that psycho-
sis was significantly more likely than most incident non-
psychotic disorders among CHR patients and that it was 
significantly less likely than most incident nonpsychotic 
disorders among HSC patients.
Similar specificity of psychotic outcomes has also been 
observed in other studies of at-risk cohorts. A  recent 
meta-analysis of 6 population-based studies of mostly 
adolescents and young adults showed that persons who 
reported subthreshold psychotic experiences developed 
psychotic clinical outcomes with a relative risk of 3.5, while 
nonpsychotic clinical outcomes developed with a relative 
risk of 1.4).44 Our findings are also similar to those recently 
reported from a Melbourne CHR cohort,27 where psycho-
sis emerged in 27.3% of the total sample (compared with 
our merged sample 19.6%, figure 1), depression emerged 
in approximately 7.3% (compared with 4.4%), and anxiety 
disorder emerged in 13.9% (compared with 5.2%).
As noted, the similar rates of emergent nonpsychotic 
disorders across the CHR and HSC groups were fairly 
low (supplementary table  2). On an annualized basis, 
these low rates are, however, generally higher than inci-
dent rates of nonpsychotic disorders in population-based 
studies of adolescents and young adults,45–54 consistent 
with CHR and HSC patients representing selected help-
seeking clinical samples. By contrast, annualized rates of 
emergent depression or anxiety in the CHR group were 
lower than in population-based studies of adolescents or 
young adults at risk for depression because of subsyn-
dromal depressive symptoms52,55,56 (but see Jonsson U 
and colleagues53) or at risk for anxiety disorder because 
of subsyndromal anxiety.54 Rates of emergent depression 
or anxiety in our CHR group were also lower than those 
in clinical samples randomized into selective or indicated 
prevention study control groups.57–73
Another important finding relates to study differ-
ences observed. Rates of emergent psychosis were lower 
Table 3. Within Group Analyses Comparing Emergent Psychosis to Other Emergent Disorders
Merged CHR Sample Emergent Disorder Incidence Rates Cochran’s Q df P value
Baseline bipolar excluded Psychosis 52/267 (19.5%) 43.7 1 <.001
Bipolar 3/267 (1.1%)
Baseline nonbipolar excluded Psychosis 30/125 (24.0%) 7.7 1 .005
Nonbipolar mood 12/125 (9.6%)
Baseline anxiety excluded Psychosis 34/152 (22.4%) 8.3 1 .004
Anxiety 14/152 (9.2%)
Any baseline mood/anxiety excluded Psychosis 17/72 (23.6%) 0.9 1 .353
Any mood/anxiety 12/72 (16.7%)a
Merged HSC Sample Emergent Disorder Incidence Rates Cohran’s Q df P value
Baseline bipolar excluded Psychosis 3/171 (1.8%) 0.2 1 .655
Bipolar 2/171 (1.2%)
Baseline nonbipolar excluded Psychosis 3/107 (2.8%) 3.0 1 .083
Nonbipolar mood 9/107 (8.4%)
Baseline anxiety excluded Psychosis 1/115 (0.9%) 6.4 1 .011
Anxiety 9/115 (7.8%)
Any baseline mood/anxiety excluded Psychosis 1/76 (1.3%) 12.2 1 <.001
Any mood/anxiety 15/76 (19.7%)b
Notes: Nonbipolar, nonbipolar mood disorder; effect CHR vs HSC, - OR from logistic regression model including term for study.
aEmergent cases do not sum to 3 + 12 + 14 = 29 for 2 reasons: (1) in 1 PREDICT CHR patient 2 emergent nonpsychotic disorders 
appeared at the same time point (see text), and (2) unlike in the analyses above patients are considered emergent cases only if  no disorder 
is present at baseline.
bEmergent cases do not sum to 2 + 9 + 9 = 20 for second reason above.
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in PREDICT than in the NAPLS-1, and specificity of 
the emergent psychosis outcome was partially related to 
this difference. In PREDICT this rate within the CHR 
patient group did not differ significantly from that for 
most incident nonpsychotic disorder groups (supple-
mentary table 3); however, psychosis remained the only 
emergent disorder that was significantly more likely in 
CHR patients than in HSC patients (table 2). Analyses 
indicated the study difference on emergent psycho-
sis was partly accounted for by lower baseline severity 
of PREDICT CHR patients on several measures. The 
duration of the CHR syndrome, associated in previous 
samples with baseline functioning74 and conversion,75 
may have shorter in PREDICT as well, although these 
data were not collected systematically in NAPLS-1. It is 
possible that the PREDICT exclusion antipsychotics led 
some severely ill or long duration CHR patients not to 
contact us. Alternatively, when a CHR clinic first opens 
more severely ill or longer duration patients may be pref-
erentially sampled initially, removing them from subse-
quent sampling. Further work on prognostic variables in 
relation to a general lowering of conversion rates in CHR 
samples in recent years75 is indicated.
Limitations
The requirement for DSM-IV structured diagnostic 
interview completion in the present report led to selection 
of patient subsamples in both studies. The CHR rate of 
emergent psychosis in the current subsample (NAPLS-1 
24.2%, PREDICT 12.6%, table 2) is somewhat lower than 
the raw conversion rates in the full sample (NAPLS-1 
29.4%25 PREDICT 19.3%). These differences are largely 
due to conversions recorded after the last DSM-IV diag-
nostic interview in both studies that were not counted as 
cases of incident psychosis in the present analyses. The 
structured interview completion requirement also selected 
for a CHR sample of somewhat lower clinical severity on 
several measures, especially in NAPLS-1 (see full sam-
ple25) but also in PREDICT, and also to higher rates of 
baseline antipsychotic in NAPLS-1 (see full sample42).
Another limitation is the different rates of incident 
anxiety disorder in PREDICT vs NAPLS-1. Baseline 
rates of anxiety disorder were similar in the 2 studies 
(table 1), and differences between studies on other meas-
ures did not account for the incident anxiety differences. 
Because NAPLS-1 data were collected in independent 
protocols,30 structured interviews for DSM-IV disorders 
were not standardized across sites, and there are no fields 
in the database to identify which interviews were used in 
which patients. Thus, we cannot determine whether inci-
dent anxiety differences relate to interview differences.
A third limitation concerns sample size. Although our 
combined samples were relatively large, samples in the 
sensitivity analyses, and particularly in analyses excluding 
patients with any baseline affective or anxiety disorder, 
were smaller (supplementary tables 1 and 2). In the analy-
ses with the smallest sample sizes, statistical power was 
sufficient to detect the emergence of any nonpsychotic 
disorder as significantly different between groups if  the 
effect size was medium (as large as 0.4676). The main find-
ings still seem convincing, however, since the observed 
CHR vs HSC effect size for any nonpsychotic disorder 
was very small at 0.05 (supplementary table  2) and the 
large effect size for psychosis (1.02) led to sufficient power 
to detect the CHR vs HSC difference as statistically sig-
nificant despite the analyses with smaller sample sizes 
(supplementary table 1).
A fourth limitation is that SIPS versions varied across 
site and over time in the NAPLS-1 sample and between 
NAPLS-1 and PREDICT. This variation is unlikely to 
have seriously influenced study conclusions, because the 
primary changes in the SIPS during this period involved 
adding explicit ratings of symptom qualifiers that had 
previously been included as free text fields, and thus the 
definitions of CHR were unchanged.77
A final area of limitation involves the HSC patients. 
While this group offers advantages as a comparison 
group in that their recruitment was identical to that CHR 
patients, the distinction between groups is that CHR 
patients did, and HSC patients did not, meet criteria for 
a current CHR syndrome. Unfortunately neither study 
permitted structured determination of whether HSC sub-
jects had ever met CHR syndrome criteria.78 Future stud-
ies should compare emergent outcomes between CHR 
cases and age-matched psychiatric patients who never 
met CHR criteria.
Conclusion
The clinical high-risk syndrome is unusual as a research 
diagnostic entity in that it specifies risk for a future disor-
der. Its utility as a research diagnostic entity thus depends 
in large part upon whether it can indeed predict increased 
likelihood of conversion to psychosis and whether it can 
do so with specificity relative to other incident disorders. 
In our 2 samples the differential risk for developing psy-
chosis when compared with help-seeking comparison 
patients was substantial and contrasted sharply with no 
observed difference in risk for bipolar disorder, nonbipo-
lar mood disorder, and anxiety disorder. Risk for emer-
gent nonpsychotic disorders was fairly low and lower 
than that reported in previous studies selecting specifi-
cally for risk of affective or anxiety disorders. We inter-
pret these findings to indicate that the CHR syndrome 
does not identify patients at a globally increased risk for 
psychopathology, but instead points towards a specific 
risk for psychosis, at least in these samples.
Although our data indicate that the CHR criteria iden-
tify patients at specific risk for psychosis, it should also 
be noted that nonpsychotic disorders did emerge in CHR 
patients, just as they did in non-CHR patients and at 
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comparable rates, and that these emergent nonpsychotic 
disorders represent important clinical prevention targets 
in both CHR and non-CHR patients.
Our findings suggest that the CHR syndrome does 
offer a specific marker for use in research on predic-
tors and mechanisms of developing psychosis and, in 
addition, suggest a number of future directions. In the 
research arena, the CHR syndrome may represent a fairly 
late stage in the development of frank disorder,18,79–81 and 
the specificity of diagnostic outcome for patients at an 
earlier stage of psychotic illness should be investigated. 
Additional population-based studies that examine mark-
ers of risk for multiple disorders and their relation to 
multiple diagnostic outcomes would be most welcome. In 
the clinical arena intervention studies should investigate 
whether existing treatments differentially prevent specific 
diagnostic outcomes, whether prevention specificity var-
ies by illness stage, and whether new treatments that tar-
get specific outcomes can be developed.
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